Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.10 USD
Change Today -0.12 / -3.73%
Volume 229.1K
GENE On Other Exchanges
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

genetic tech ltd-sp adr (GENE) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/15 - $11.00
52 Week Low
01/23/15 - $1.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENETIC TECH LTD-SP ADR (GENE)

genetic tech ltd-sp adr (GENE) Related Bloomberg News

View More Bloomberg News

genetic tech ltd-sp adr (GENE) Related Businessweek News

No Related Businessweek News Found

genetic tech ltd-sp adr (GENE) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders. The company also provides DNA based tests comprising peace of mind paternity, legal paternity, antenatal DNA, deceased estate, DNA profiling, grandparent, immigration, sibling, twins, and Y-chromosome DNA tests. In addition, it offers DNA testing, canine health register, forensics, and breed identification services to animals. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited is headquartered in Fitzroy, Australia.

genetic tech ltd-sp adr (GENE) Top Compensated Officers

Chief Executive Officer, Chief Operating Offi...
Total Annual Compensation: A$14.4K
President of Phenogen Sciences Inc.
Total Annual Compensation: A$299.8K
Director of Global Licensing & Intellectual P...
Total Annual Compensation: A$140.4K
Scientific Director
Total Annual Compensation: A$125.7K
Quality and Business Operations Director
Total Annual Compensation: A$98.7K
Compensation as of Fiscal Year 2014.

genetic tech ltd-sp adr (GENE) Key Developments

Genetic Technologies Limited Appoints Brian Manuel as Chief Financial Officer

Genetic Technologies Limited announced the appointment of Mr. Brian Manuel as Chief Financial Officer, effective June 15, 2015. Mr. Manuel is a Fellow Chartered Accountant and a Fellow of the Governance Institute of Australia. Of his 25 plus years of experience, more than a decade has been at the CFO level for companies listed on the ASX including the Biotech Company Cellestis Ltd, as the CFO and Company Secretary until its acquisition in 2011.

Genetic Technologies Limited Appoints Eutillio Buccilli as Director

Genetic Technologies Limited announced that Mr. Eutillio Buccilli has been appointed Director of the company on ‘casual appointment’, in that the new appointee will be required to submit himself for re-election at the upcoming AGM, as per article 19.4 of the company's constitution. The initial Director's interest notice - Appendix 3X, on behalf of Mr. Buccilli is attached. Mr. Eutillio Buccilli Mr. Buccilli joined the company in June 2014 as chief financial officer. in November 2014, Mr. Buccilli was appointed to the position of chief operating officer and chief financial officer and was subsequently appointed chief executive officer in February 2015.

Genetic Technologies Limited Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Genetic Technologies Limited reported consolidated earnings results for the year ended December 31, 2014. Revenue from continuing operations - genetic testing services was $1.3 million against $2.0 million last year. Loss from continuing operations before income tax expense was $4.8 million against $5.1 million last year. Loss attributable to owners of the company was $4.8 million or $0.68 per basic and diluted share against $5.1 million or $1.01 per basic and diluted share last year. Net cash flows used in operating activities was $5.8 million against $5.2 million last year. Purchase of property, plant and equipment was $0.2 million against $0.02 million last year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENE:US $3.10 USD -0.12

GENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $38.74 USD -1.28
Sonic Healthcare Ltd A$21.37 AUD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation GENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 76.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECH LTD-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at